The interplay between cancer and inflammation is a critical area of research with profound clinical implications. Inflammation serves as a significant therapeutic target, with anti-inflammatory drugs showing promise in cancer prevention and treatment. Immune checkpoint inhibitors have transformed cancer therapies, enhancing patient survival across various malignancies, though challenges such as immune-related adverse events and resistance remain. The identification of biomarkers has facilitated personalized treatment approaches, guiding therapy choices based on individual inflammatory profiles and genetic backgrounds. Combination therapies integrating immunotherapy and anti-inflammatory strategies are emerging as effective methods to enhance therapeutic efficacy. Future research focuses on novel therapeutic targets, advanced biomarker development, and innovative combination strategies while addressing tumor heterogeneity and improving the safety of immunotherapies. The interplay between angiogenesis and inflammation is also explored, revealing how pro-angiogenic factors like VEGF are upregulated in inflamed tissues, facilitating tumor progression. The integration of basic research, translational studies, and clinical insights, alongside the exploration of the microbiome’s role in cancer and inflammatory diseases, offers innovative pathways for advancing therapeutic strategies. These interdisciplinary approaches are key to understanding complex disease mechanisms, refining treatment paradigms, and improving patient outcomes. Overall, ongoing research promises to reshape cancer treatment and improve patient outcomes through a deeper understanding of inflammation’s role in oncogenesis and therapy.